Nerviano becomes a targeted PARP player
Two cast-offs comprise the private group's attempts to hit PARP1 and PARP7.
Truqap could fill a prostate cancer gap
The AKT inhibitor prevails in hormone-sensitive disease, but other studies have been delayed.
Targeted lung cancer niche sees a German pharma battle
But could toxicity be holding back filing plans?
Kyowa buys into menin, but it's not Syndax's
Syndax scored the first menin approval, but Kura is first with a licensing deal.
The markets stress over Nuvectis
NXP800 yields neither severe thrombocytopenia, nor any responses.
